The Untested Molecule: Orforglipron Was Just Approved. Nobody Measured What It Does to Testosterone.

Today — April 1, 2026 — the FDA approved orforglipron (Foundayo), the first non-peptide oral GLP-1 receptor agonist for obesity. Eli Lilly will begin shipping it through LillyDirect on April 6 at $149 per month. It will reach millions of patients — including millions of men — within weeks.

Here is what was not measured in any of the clinical trials that led to this approval: testosterone, LH, FSH, SHBG, estradiol, semen parameters, sexual function scores, or any reproductive endpoint of any kind.

If this were simply another injectable GLP-1 RA, that void would be concerning but at least partially addressable — we have accumulating data on semaglutide and tirzepatide's hormonal effects, however incomplete. But orforglipron is not another injectable. It is a fundamentally different molecule with a fundamentally different pharmacological profile. The data from peptide GLP-1 agonists cannot be cleanly transferred to it. And nobody has generated the data that would tell us whether the transfer is safe.

What Makes Orforglipron Different

Every GLP-1 receptor agonist approved before today — semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide — is a peptide. These are large molecules that bind the receptor's orthosteric pocket (the same site where the body's own GLP-1 binds) and activate both major downstream signaling arms: G protein coupling (which drives cAMP production) and β-arrestin recruitment (which drives receptor internalization and separate signaling cascades).

Orforglipron is none of this. It is a small molecule — a non-peptide, orally bioavailable compound that binds an allosteric site within the receptor's transmembrane domain, distinct from the peptide-binding domain. And it activates the receptor with a pronounced signaling bias.

This is not a minor pharmacological footnote. The difference between full dual-pathway activation and G protein-biased partial agonism changes how every cell that expresses GLP-1R responds to the drug. And one of those cells — the Leydig cell, the factory that produces testosterone — is at the center of a story that has already gotten complicated with the peptide agonists.

Why β-Arrestin Matters in Testes

GLP-1 receptors are expressed on human Leydig cells, Sertoli cells, and germ cells. This was established by Caltabiano et al. (Andrology, 2020) and confirmed by subsequent immunohistochemistry studies. The receptor is not incidental — Leydig cells themselves secrete GLP-1, suggesting a paracrine autocrine loop within the testis.

In my previous analysis of the GLP-1 testicular paradox, I described three layers of effect: metabolic restoration (weight loss raises testosterone by breaking the metabolic trap), direct testicular suppression (GLP-1R activation downregulates LHCGR and suppresses steroidogenesis in organoid models), and serotonergic blunting (5-HT2C-mediated libido suppression). The evidence showed that in obese men, metabolic benefits overwhelm testicular suppression — but in lean men, the balance may tip the other way.

That analysis was built on data from peptide GLP-1 RAs. Here is what changes with orforglipron:

This is not speculation. Sloop et al. (Science Translational Medicine, 2024) directly characterized orforglipron's signaling bias — confirming partial G protein agonism with negligible β-arrestin engagement — and specifically noted this profile may reduce receptor tachyphylaxis. But that paper measured signaling in pancreatic and metabolic cell contexts. Nobody has measured what this biased profile does in testicular cells.

Three Scenarios, Zero Data

The signaling divergence creates three plausible scenarios for orforglipron's effect on male testosterone:

Scenario	Mechanism	Clinical Implication
Better than peptide GLP-1 RAs	No β-arrestin → no LHCGR downregulation → Leydig cells retain LH sensitivity. cAMP/PKA may directly support steroidogenesis. Weight loss benefit preserved.	Orforglipron raises testosterone more effectively than semaglutide, even in lean men. Would be the preferred GLP-1 RA for hypogonadal patients.
Equivalent	Testicular suppression is primarily cAMP-driven (not β-arrestin-driven). Both pathways converge on similar downstream effects. Net effect matches peptide agonists.	Population-dependent thesis from peptide data applies. Obese men benefit, lean men may not. Standard monitoring sufficient.
Worse than peptide GLP-1 RAs	No β-arrestin → no receptor internalization → prolonged uninterrupted cAMP activation in Leydig cells → chronic overstimulation → steroidogenic exhaustion or paradoxical suppression.	Orforglipron suppresses testosterone more than injectables. Lean men especially at risk. Would require specific reproductive monitoring.

Each scenario is pharmacologically plausible. None can be ruled out. The data that would distinguish between them — a simple pre/post testosterone measurement in male ATTAIN-1 participants — was never collected.

What the Trials Actually Measured

ATTAIN-1 enrolled 3,127 patients with obesity across nine countries for 72 weeks. Approximately 36% were male — roughly 1,126 men taking a novel GLP-1 RA for over a year. The trial measured body weight, waist circumference, blood pressure, lipids, and HbA1c. It did not measure testosterone, LH, FSH, SHBG, free testosterone, or any sexual function score.

ATTAIN-2 — the type 2 diabetes arm — likewise reported metabolic and glycemic endpoints. No reproductive hormones.

ACHIEVE-3 — the head-to-head versus oral semaglutide — measured glycemic superiority. No reproductive hormones.

The blood was drawn. The samples existed. The assays were not run.

For context: what we know from peptide GLP-1 RA trials

Researchers studying semaglutide and tirzepatide have at least begun measuring testosterone in male participants — even if the data remains incomplete. Cannarella et al. (2025) showed 100% normalization of testosterone in 83 obese hypogonadal men on tirzepatide. Portillo Canales (ENDO 2025) showed testosterone normalization in 77% of 110 men on mixed GLP-1 RAs. A 2026 systematic review confirmed GLP-1 RAs as a class raise total testosterone, LH, and FSH in obese men.

All of this is for peptide agonists. For orforglipron, the count is zero.

The DTC Acceleration

This void does not exist in isolation. It exists in the context of a direct-to-consumer healthcare apparatus that will begin dispensing orforglipron within days.

Lilly has announced that Foundayo will be available through LillyDirect starting April 6 — five days from now — with home delivery at $149/month for the starting dose. This is the same DTC pipeline I described in my analysis of the testosterone information crisis: rapid access, minimal clinical gatekeeping, and no framework for monitoring what isn't being measured.

The men who will receive orforglipron through DTC channels in the coming weeks will include:

• Men with undiagnosed functional hypogonadism (prevalence ~30% in obese men)
• Men currently on TRT who add orforglipron for weight loss (no interaction data)
• Men on enclomiphene or clomiphene attempting axis restoration (unknown GLP-1R interaction with SERM-stimulated Leydig cells)
• Younger men with fertility concerns (no semen parameter data for orforglipron)

None of these men will receive testosterone monitoring as part of their orforglipron prescription. Not because clinicians chose to omit it — because the evidence base that would mandate it does not exist.

What Should Exist

The Pattern

This is the thirty-fourth article I have published. In at least a dozen of them, the core finding has been the same: a drug that affects the HPG axis was approved, prescribed, or widely adopted without anyone measuring what it does to testosterone. Opioids. SSRIs. Antipsychotics. Finasteride. GnRH agonists in non-oncology settings. Anticonvulsants. Statins. Now GLP-1 receptor agonists — and specifically, the first one with a novel signaling mechanism that makes prior class data non-transferable.

The information crisis in men's reproductive endocrinology is not a single failure. It is a structural feature of drug development: testosterone is not measured because testosterone is not a primary endpoint, and testosterone is not a primary endpoint because the regulatory framework does not require it, and the regulatory framework does not require it because the evidence that would justify the requirement was never generated. The loop closes.

Orforglipron will be in the hands of patients before the end of this week. The testosterone question will remain unanswered until someone decides it matters enough to fund a study. Based on the pattern established across every other drug class that affects the HPG axis, that study will come years after the prescriptions — if it comes at all.